Neurogene stops Batten gene therapy after FDA denies request, dealing double dose of bad news Read more 

Incyte's $750M buyout rocked by pause on key trial, asset cull Read more 

Nearing potential FDA approval, BridgeBio shows additional positive data on ATTR-CM candidate acoramidis Read more 

Multiomics in Metabolic Disease

Genetic and biological factors significantly influence the risk of metabolic disorders such as obesity, type 2 diabetes, and dyslipidemia. Advances in ‘omics’ technologies—genomics, epigenomics, transcriptomics, [...]

Go to Top